EGM
INZY

Engineers Gate Manager’s Inozyme Pharma INZY Stock Holding History

Engineers Gate Manager’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,519
Closed -$61.9K – 2092
2023
Q4 		$61.9K Buy
+14,519
New +$51.6K ﹤0.01% 1825

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Engineers Gate Manager's INZY Position: Q1 2024 in Review

Engineers Gate Manager sold out of Inozyme Pharma (INZY) in Q1 2024, closing a stake of 14,519 shares — an estimated $61.9K sold.

Engineers Gate Manager first reported a position in INZY in Q4 2023 and held it in 1 quarter. The position peaked at $61.9K in Q4 2023. 89 funds tracked by Wall St. Rank hold INZY as of Q1 2024.

  • Engineers Gate Manager reported no remaining Inozyme Pharma position as of Q1 2024 after selling out during the quarter.
  • Engineers Gate Manager sold 14,519 Inozyme Pharma shares in Q1 2024, an estimated $61.9K.
  • Engineers Gate Manager first reported a position in Inozyme Pharma in Q4 2023 and held it in 1 quarter.
  • Engineers Gate Manager's Inozyme Pharma position peaked at $61.9K in Q4 2023.
  • 89 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2024.

Based on Engineers Gate Manager's 13F filing for Q1 2024, filed 15 May 2024.